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Lower back pain in degenerative spinal lumbar disease 
(DSLD) is strongly linked with the inflammatory reaction 
that is associated with intervertebral disc degeneration1) 
and back muscle degeneration.2) Nonsteroidal anti-inflam-
matory drugs (NSAIDs) are most frequently prescribed for 
pain management in DSLD.3,4) NSAIDs inhibit the activ-
ity of cyclo-oxygenase, thereby inhibiting the synthesis of 
prostaglandins and thromboxane. There are 2 categories: 
non-selective NSAIDs (ns-NSAIDs) and cyclooxygenase 2 
(COX-2) selective inhibitors (coxibs). These drugs are fre-
quently used for long periods of time by elderly patients.5) 
However, NSAIDs are not always appropriately prescribed, 
and some authors have called attention to the high preva-
lence of inappropriate prescription of these drugs, espe-
cially in elderly patients, because NSAIDs are known to 
carry risks to the gastrointestinal (GI) and cardiovascular 
(CV) systems by increasing GI bleeding and thrombo-
embolic events.6) It is well established that ns-NSAIDs 
increase the risk of serious GI events. A person treated 
with NSAIDs has a 3–5 times higher risk of developing GI 
complications than a person not treated with these drugs.7) 
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Furthermore, in severe cases, ns-NSAIDs can cause death 
due to GI bleeding.8,9) Mortality caused by GI complica-
tions is 16,500 deaths per year in the USA, which is com-
parable to the number of deaths from acquired immuno-
deficiency syndrome (AIDS).10) While coxibs have a better 
GI safety profile than ns-NSAIDs,11) long-term use and 
high dose of coxibs may increase CV risk.12-14) In addition, 
ns-NSAIDs may have a similar deleterious CV effect.15-17) 
Recently, some meta-analyses have tried to identify 
specific NSAIDs that are associated with relatively lower 
CV risk.18,19) Appropriate selection of NSAIDs should be 
driven by the assessment of the GI and CV risks of individ-
ual patients.3,20) Many authors have recommended specific 
therapeutic guidelines using various tools to evaluate GI 
and CV risks.9,21) Despite the frequent use of NSAIDs for 
patients with degenerative lumbar spinal disease (DLSD) 
and the known risks on the GI and CV systems, the preva-
lence of such risks and current prescription patterns of 
NSAIDs have not been fully investigated. 
Therefore, we sought to (1) identify the prevalence 
of GI and CV risks in patients with DLSD; (2) investigate 
the relationship between these risks and patient demo-
graphic variables such as age, sex, and body mass index 
(BMI); and (3) analyze the pattern of NSAID prescription 
in our cohort of subjects with these risks.
METHODS
Patients
We conducted a retrospective cross-sectional observa-
tional study of patients with symptomatic DLSD who 
were scheduled for lumbar decompression surgery with 
or without posterolateral fusion. Data from patients were 
collected from June 2013 to July 2015. Patients were con-
sidered for inclusion in the study if they met the following 
criteria: (1) diagnosis of symptomatic DLSD; (2) age ≥ 50 
years; (3) scheduled for decompression surgery with or 
without posterolateral fusion; and (4) verbal consent from 
the patients or their legal representatives. Exclusion cri-
teria were (1) age < 50 years and (2) refusal to participate 
in the study. A total of 153 patients were enrolled in this 
study. This study was approved by the Institutional Review 
Board of Severance Hospital (IRB No. 4-2014-0571). 
GI and CV Risk Evaluation
To assess the risk factors for GI complications, we used 
the GI Standardized Calculator of Risk for Event (SCORE) 
system for each patient (Appendix 1). Developed by the 
Division of Immunology and Rheumatology at Stanford 
University,22) the SCORE tool assigns points to different 
patient characteristics to stratify patients according to the 
risk of developing serious GI complications. A Northern 
California Health Maintenance Organization (HMO) 
developed a treatment guideline, indicating that different 
NSAIDs should be recommended for different patients, 
depending on the total number of points assigned by the 
SCORE tool.23) For the purpose of this study, 6 predictors 
of the SCORE system were investigated: age, diagnosis of 
rheumatoid arthritis, current health status, proportion of 
time taking steroids, history of previous GI side effects, and 
history of previous GI hospitalization.23) This GI SCORE 
was determined on each patient’s admission day for sur-
gery. 
CV risk was also evaluated by checking the presence 
of metabolic syndrome. Metabolic syndrome comprises 
a number of conditions, including obesity, atherogenic 
dyslipidemia, impaired fasting glucose, and hypertension 
(HTN), the prevalence of which has rapidly increased.24) 
Among patients with metabolic syndrome, a significantly 
increased risk of CV disease25) and mortality26) are reported. 
Therefore, identifying metabolic syndrome is thought to 
be a simple method of CV risk evaluation. The presence of 
metabolic syndrome was defined using the National Cho-
lesterol Education Program (NCEP ATPIII).27) The cutoffs 
established for Korean adults, as proposed by The Korean 
Society for the Study of Obesity, were adopted for the diag-
nosis of abdominal obesity.28) The criterion for diagnosis of 
high glucose was adopted from the guidelines established 
by the American Diabetes Association.29) Subjects with 3 
or more of the following characteristics were considered 
to have metabolic syndrome: abdominal obesity (waist 
circumference [WC] ≥ 90 cm in men and ≥ 80 cm in wom-
en); hypertriglyceridemia ≥ 150 mg/dL; low high-density 
lipoprotein cholesterol (HDL-C) < 40 mg/dL in men and < 
50 mg/dL in women; high blood pressure ≥ 130/85 mmHg 
or use of antihypertensive medication; and high fasting 
glucose ≥ 100 mg/dL or under treatment for diabetes. The 
measurement of WC and a laboratory test were performed 
on the day of hospital admission. Based on these criteria, 
we assigned to each patient a metabolic syndrome score 
between 0 and 5 points (Appendix 2). 
Evaluation of the Relationship between GI and CV 
Risks and Demographic Variables
Demographic data such as age, sex, and BMI were col-
lected on the day of admission. The relationship between 
GI and CV risks and these variables was evaluated by sta-
tistical methods. 
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Evaluation of the Pattern of NSAID Prescription
Data on the types of NSAID and gastroprotective agents 
prescribed by physicians were obtained at the outpatient 
clinic office. To evaluate patterns of NSAID prescription, 
patients underwent assessment of GI and CV risks and 
were classified into 6 subgroups according to the guidelines 
for prevention of NSAID-related ulcer complications.21) 
Then, we investigated the conformity of the current pre-
scription to the recommendations of the guidelines. 
Statistical Analysis
The descriptive analysis of the patients included demo-
graphic variables, diagnosis, duration of symptoms, and 
duration of medication. All continuous variables were 
expressed as median with interquartile range (IQR) be-
cause data were tested for normality using the Shapiro-
Wilk test and were found to be non-normally distributed. 
Prevalence of GI and CV risks was expressed as median 
with IQR for continuous variables and frequency and 
percentage for discrete data. Patient distribution of GI 
and metabolic syndrome scores was plotted using an x-y 
plot. In the analysis of the relationship between GI / CV 
risks and demographic variables, a Spearman correlation 
analysis and nonparametric regression analysis using lo-
cally estimated scatterplot smoothing curves with a span 
of 80% were conducted for continuous variables such as 
age and BMI. Differences in GI and metabolic syndrome 
scores between sexes were tested using the Mann-Whit-
ney U-test. To identify prescription patterns of NSAIDs 
in DLSD patients, a 2-dimensional scatter plot with GI 
SCORE as the X-axis and metabolic syndrome score as the 
Y-axis was drawn. It was divided into 6 regions according 
to guidelines for the prevention of NSAID-related ulcer 
complications. Conformity of actual prescriptions with 
recommendations in the guidelines was calculated as per-
centage. MedCalc ver. 11.6 (MedCalc Software, Mariaker-
ke, Belgium) and R ver. 3.1.0 (Comprehensive R Archive 




This study included 153 patients older than 50 years who 
were planning to have lumbar decompression surgery. 
The patient demographic and clinical characteristics are 
summarized in Table 1. The median age was 70 years, and 
most patients were women (male : female = 109 : 44). The 
median value of BMI was 24.4 kg/cm2. The diagnosis of 
DLSD was spinal stenosis in 75.1% (n = 115 / 153), herni-
ated lumbar disc in 13.7% (n = 21 / 153), and spondylo-
listhesis in 13% (n = 13 / 153) of patients. The duration of 
symptoms before surgery was 3.2 years and the duration of 
medication was 0.7 years. 
Prevalence of GI and CV Risks
The median GI SCORE was 16.0. The GI SCORE system 
was used to classify subjects into 4 groups: low (< 10), 
moderate (11–15), high (16–20), or very high (> 20) GI 
risk groups. More than half of patients (59.5%; n = 92 / 
153) had high or very high GI risk, whereas only 3.3% had 
low GI risk. The median metabolic syndrome score was 
Table 1. Demographic Data (n = 153)
Variable Value
Age (yr) 70.0 (64.0–74.0)
Sex (female : male) 109 : 44
Body mass index (kg/cm2) 24.4 (22.7–26.7)
Diagnosis
   Spinal stenosis 115 (75.1)
   Herniated disc 21 (13.7)
   Spondylolisthesis 13 (8.5)
Duration of symptom (yr) 3.2 (2.9–3.6)
Duration of medication (yr) 0.7 (0.5–0.9)
Values are presented as median (interquartile range) or number (%).
Table 2. Prevalence of GI and CV Risks
Variable Value
GI score 16 (15–18)
Grade of GI score
   Low risk (≤ 10) 5 (3.3)
   Moderate risk (11–15) 57 (37.2)
   High risk (16–20) 80 (52.3)
   Very high risk (> 20) 11 (7.2)
Metabolic syndrome score 3 (2–4)
Presence of metabolic syndrome
   No 52 (34)
   Yes 101 (66)
Values are presented as median (interquartile range) or number (%).
GI: gastrointestinal, CV: cardiovascular.
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3.0 and 66% (n = 101 / 153) of patients had metabolic syn-
drome, which corresponded with CV risk (Table 2). The 
rate of simultaneous GI and CV risk was 40.5% (n = 62 / 
153; GI SCORE, > high and metabolic syndrome, yes) (Fig. 
1). 
Relationship between GI / CV Risk and Demographic 
Variables
GI risk showed a positive relationship with age (rho = 0.63, 
p < 0.001) and CV risk showed a positive relationship with 
BMI (rho = 0.43, p < 0.001) (Fig. 2). Sex was not correlated 
with GI risk (p = 0.177; GI SCORE: median, 15.5 [IQR, 
14.5–18.0] for male vs. median, 16.0 [IQR, 15.0–18.0] for 
female) or CV risk (p = 0.184; metabolic syndrome score: 
median, 3.0 [IQR, 2.0–4.0] for male vs. median, 3.0 [IQR, 
2.0–4.0] for female) (Fig. 3). GI risk was more positively 
correlated with age in patients with metabolic syndrome 
(rho = 0.65, p < 0.001) than patients without metabolic 
syndrome (rho = 0.59, p < 0.001). However, there was no 
significant correlation between GI risk and BMI regardless 
of the presence of metabolic syndrome (p > 0.05) (Fig. 4). 
Pattern of NSAID Prescription
The most commonly prescribed pattern of NSAIDs in 
DLSD patients was ns-NSAIDs alone (n = 71, 46.4%) fol-
lowed by alternative therapy (n = 48, 31.4%) regardless 
of the presence of GI and CV risk factors. All alternative 
therapy comprised the prescription of opioids. The pre-
scription of NSAIDs was not in accordance with current 
guidelines or recommendations (Table 3).
Fig. 1. The scatter plot according to gastrointestinal (GI) and cardio-
vascular risk. Each region is marked according to American College of Gas-
































































































Fig. 2. A scatter plot with regression curve. Gastrointestinal (GI) score and metabolic syndrome score are positively correlated with age and body 
mass index (BMI), respectively. Correlation analysis was performed using a Spearman method, which produces a correlation coefficient (rho) with a 
significance level (p). Nonparametric regression analysis was performed using locally estimated scatterplot smoothing curves with a span of 80%.
Fig. 3. Relationship between GI/CV risk and demographic variables 
(age, sex, and BMI). The arrows marked with O indicate a significant 
correlation, other wise the correlation is nonsignificant. Spearman 
correlation analysis was performed for age and BMI. A Mann-Whitney 
U-test was performed for sex. GI: gastrointestinal, CV: cardiovascular, 
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DISCUSSION
Our results show that the prevalence of GI and CV risks or 
both in patients with DLSD was relatively high compared 
to that in the general population. The GI risk in DLSD 
patients was about 60% in this study, which was higher 
than the average prevalence of high GI risk (45%) among 
the general population of orthopedic patients visiting out-
patient clinics in Korea.30) The CV risk in this study was 
66% and this was higher than that for patients with knee 
osteoarthritis in Korea (53%).31) Our study is the first to 
describe the prevalence of DLSD patients with both GI 
and CV risks, and the rate was about 40%. 
These figures underscore the need for more care-
ful assessment of GI and CV risks in DLSD patients since 
they are relatively older and are often chronic users of 
NSAIDs. Lanas et al.20) reported that among patients with 
osteoarthritis who need treatment with NSAIDs, 22.3% 
had a high GI risk, 44.2% had a high CV risk, and 15.5% 
had a high combined risk. Compared to that study, the 
Fig. 4. A Co-plot according to the presence of metabolic syndrome. Gastrointestinal (GI) score correlates positively with age more strongly in patients 
with metabolic syndrome (rho = 0.65) than in patients without metabolic syndrome (rho = 0.59). There is no significant correlation between GI score and 
body mass index (BMI) regardless of the presence of metabolic syndrome.
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Table 3. Pattern of NSAID Prescription
Variable Region #1 Region #2 Region #3 Region #4 Region #5 Region #6 Total (%)
Recommendation NSAIDs  alone
NSAIDs + PPI/
misoprostol








Number (%) 1 (0.7) 22 (14.4) 29 (19.0) 4 (2.6) 35 (22.9) 62 (40.5) 153 (100)
Current prescription 
   NSAIDs alone 0 6 13 4 20 28 71 (46.4)
   NSAIDs + PPI/misoprostol 0 1 2 0 3 7 13 (8.5)
   COX-2 inhibitor or alternative therapy 0 1 2 0 3 13 19 (12.4)
   Naproxen + PPI/misoprostol 0 1 0 0 0 1 2 (1.3)
   Alternative therapy 1 13 12 0 9 13 48 (31.4)
Conformity (%) 0 5 7 0 0 21 　
NSAID: nonsteroidal anti-inflammatory drug, PPI: proton pump inhibitor, COX-2: cyclooxygenase 2.
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results of the current study show a much higher GI and 
CV risk prevalence among patients with DLSD, although 
different tools were used to evaluate GI and CV risks in 
the 2 studies. According to the National Health Insurance 
Database of Korea, among 11,000 patients who underwent 
spine surgery, about 42% of patients had GI comorbidities, 
such as peptic ulcer disease32) and 37% of patients had CV 
comorbidity, such as myocardial infarction or congestive 
heart failure.31) Although these figures are lower than the 
prevalence of the risks revealed in this study, this still rep-
resents a relatively high rate of GI and CV comorbidities 
after spinal surgery. These results suggest that GI and CV 
risks should be recognized and evaluated as comorbid fac-
tors of spinal surgery in patients with symptomatic DLSD. 
More attention should be paid to selecting the proper 
NSAIDs for postoperative pain or persisting symptoms 
after surgery. 
We also found that the GI risk has a positive rela-
tionship with age in DLSD patients. It is well known that 
old age and chronic use of NSAIDs are the most common 
risk factors for the development of serious GI adverse re-
actions.3) A previous study found that GI risk in patients 
over 75 years is approximately twice that of patients over 
60 years.10) The current study showed that most patients 
had taken NSAIDs for quite a long period (mean, 7 
months) before spinal surgery and found that GI SCORE 
correlated positively and strongly with age. These results 
suggest the need for mandatory GI screening, especially 
for older patients. On the other hand, CV risk had a posi-
tive relationship with BMI in DLSD patients. Considering 
that obesity is a well-established CV risk factor, this result 
was predictable, but it implies that decreased physical ac-
tivity in DLSD patients can have a negative influence on a 
patient’s BMI and we should pay more attention to CV risk 
in DLSD patients with higher BMI.
Finally, prescription patterns of NSAIDs in clinical 
practice showed relatively low conformity to recommenda-
tions. Current guidelines recommend the use of selective 
COX-2 inhibitors or conventional NSAIDs with proton 
pump inhibitors in patients with high GI risk.21) How-
ever, this study showed that NSAIDs or gastroprotectives 
were often prescribed according to the physician’s habits 
and preferences rather than according to the guidelines. 
Moreover, according to the current guidelines, patients 
with combined GI and CV risk should not take NSAIDs 
or coxibs unless absolutely necessary.21) Nevertheless, this 
study revealed that most patients with DLSD were pre-
scribed NSAIDs regardless of their GI or CV risk factors. 
These results suggest that more attention should be paid to 
the guidelines to reduce these risks.
The limitations of the current study were the same 
as those of any cross-sectional observational study. The 
number of enrolled patients was small because we inves-
tigated only those subjects planning spinal surgery in a 
single spine center. Furthermore, the prevalence might 
differ depending on which screening tool is used to assess 
GI and CV risks. Despite these limitations, the high preva-
lence of GI and CV risks in patients with surgically indi-
cated symptomatic DLSD underscores the need for spine 
surgeons to execute routine GI and CV screening before 
medical treatment, especially when prescribing NSAIDs.
In conclusion, this study documented the preva-
lence and baseline profile of GI and CV risks in patients 
with symptomatic DLSD. The prevalence of GI and CV 
risks or both in patients with DLSD was relatively high 
compared to that in the general population. Two out of 3 
patients had a high GI or CV risk, and approximately 40% 
of patients had both. In DLSD patients, GI risk showed a 
positive relationship with age, whereas CV risk showed 
a positive relationship with BMI. These results highlight 
the need for individual assessment of GI and CV risks and 
selection or limitation of NSAIDs under suggested guide-
lines. However, current prescription patterns of NSAIDs 
showed relatively low conformity to the recommendations. 
Detailed recognition of GI and CV risks in patients with 
symptomatic DLSD by using effective evaluation tools is 
mandatory for optimal medical treatment. 
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Appendix 1. NSAIDs GI Risk: Standardized Calculator of Risk for Event (SCORE) Card
NSAID: nonsteroidal anti-inflammatory drug, GI: gastrointestinal.
20 
 
Table 1. NSAIDs GI Risk: Standardized Calculator of Risk for Event (SCORE) Card 
  
POINT 
Patient age in years 
40−50             8 points 51−55             9 points  
56−60            10 points 61−65            12 points  
66−70            13 points 71−75            14 points  
76−80            16 points 81−85            17 points  
> 85              18 points   
Current health status as rated by the patient 
Very well          0 points Well               1 point  
Fair                2 points Poor               3 points  
Very poor          4 points   
Does patient have rheumatoid arthritis? 
No                 0 points Yes                2 points  
Use of oral prednisone or other oral steroids in past year 
0 mo               0 points 1−3 mo            1 point  
4−6 mo            3 points 7−10 mo           4 points  
11−12 mo          5 points   
Hospitalized for GI bleeding or an ulcer? (If ‘yes’, skip #6) 
No                 0 point Yes                8 points  
Has the patient had side effects when taking NSAIDs? 
No                 0 point Yes                2 points  
Total score (add all points) 
GI risk by SCORE card; consists of 6 items; total 8 (min)−41 (max) points 
Score Grade 
8−10 points Low 
11−15 points Moderate 
16−20 points High 
21−41 points Very high 
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Metabolic syndrome is defined by the presence of at least 3 of the following components
Blood glucose ≥ 100 mg/dL (or taking hypoglycemic)
High density lipoprotein < 40 mg/dL (men) or < 50 mg/dL (women)
Triglycerides ≥ 150 mg/dL (or taking lipid-lowering agents)
Waist circumference > 90 cm (men) or 85 cm (women)
Blood pressure ≥ 130/85 mmHg (or taking antihypertensive agents)
CV risk by metabolic syndrome; consists of 5 items: total 0 (min)–5 (max) points
0–2 points No
3–5 points Yes
NSAID: nonsteroidal anti-inflammatory drug, CV: cardiovascular.
Appendix 2. NSAIDs CV Risk: Definition of Metabolic Syndrome
